Search companies

Live

IMUGENE LIMITED (ASX: IMU)

Health care · News and insights

Price unavailable

Latest IMU announcements

Announcement Insights

Imugene Advances Azer-Cel Toward Later-Stage Testing as Early Combination Responses Emerge

Imugene’s azer-cel program has reported encouraging but early Phase 1b response data alongside a clearer development timetable. The company reported a 77% response rate across Phase 1b patients and 86% in the BTK-inhibitor combination cohort, while cautioning that the combination results are early; it expects to complete enrolment in the second quarter of 2027, meet the FDA in mid-2027 and target a registrational study in the second half of 2027 or 2028. A roughly $2 million FY2026 R&D refund is intended to support recruitment, and the planned next steps remain subject to the trial’s progress and regulatory discussions.}

Updated 16 Nov 2026, 09:19 AM Sydney time
Share
SourcesImugene Receives $2.1M R&D Tax RefundAGM PresentationResults of 2026 Annual General MeetingDirector Resignation and Committee ChangesImugene selected for Poster Presentation at 2026 ASH MeetingPositive amendments to Convertible NotesQuarterly Activities/Appendix 4C Cash Flow Report
Comments

Imugene Sets Azer-Cel Milestones, Reports 77% Phase 1b Response Rate

2026-11-11 · Health care

IMU: $0.034 -5.56% · MC: $20M

At its AGM, Imugene said azer-cel had a 77% response rate across Phase 1b patients, with early BTK-inhibitor combination data showing an 86% response rate; the company cautioned that the combination results are early. It expects to complete Phase 1b enrolment in the second quarter of 2027, plans an FDA meeting in mid-2027 to discuss the registration pathway, and is targeting a registrational study in the second half of 2027 or 2028, while out-licensing discussions are underway. The AGM also approved all resolutions, and non-executive director Lesley Russell resigned, prompting committee changes.

Updated 2026-11-11 14:04
Share
SourcesAGM PresentationResults of 2026 Annual General MeetingDirector Resignation and Committee Changes
Comments

Imugene’s Azer-Cel Data Selected For Major Haematology Meeting

2026-11-05 · Health care

IMU: $0.035 +16.67% · MC: $20M

Imugene said its azer-cel study of treatment alongside BTK inhibitors in relapsed or refractory B-cell cancers has been selected for a poster presentation at the American Society of Hematology’s annual meeting in December. The company plans to present emerging Phase 1b data; shares rose around 13% on the day, alongside the update.

Updated 2026-11-05 15:33
Share
SourcesImugene selected for Poster Presentation at 2026 ASH Meeting
Comments

Imugene Wins Conditional Option to Redeem Convertible Notes Early

2026-11-03 · Health care

IMU: $0.033 -2.94% · MC: $20M

Imugene has amended terms on its convertible notes with CVI, giving it a new option to redeem some or all of the notes before maturity, but only with CVI’s prior written consent and subject to agreed conditions. The company says the change is intended to improve near-term cash-flow flexibility; the notes’ face values and warrant terms are unchanged.

Updated 2026-11-03 10:01
Share
SourcesPositive amendments to Convertible Notes
Comments

Imugene Reports 86% Response Rate in Azer-Cel Combination Trial as Cash Outflow Falls

2026-10-30 · Health care

IMU: $0.035 -7.89% · MC: $20M

Imugene reported responses in six of seven evaluable patients in its azer-cel BTKi combination cohort, an 86% response rate, while the CAR T-naïve cohort recorded an 81% response rate after quarter end. Quarterly net operating cash outflow fell 19% from the prior quarter, with staff costs down 51%; cash stood at approximately $5 million before an expected R&D tax incentive refund. The results are early and based on small patient groups, with further follow-up needed to assess response durability.

Updated 2026-10-30 09:46
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments